Funding round
Enveda Series D
Enveda, which works in drug discovery and development in Boulder, raised $150M in a Series D round announced on 4 Sep 2025, led by Premji Invest. 12 firms took part, 2 of them already investors. It is Enveda's fifth venture round on record; the one before was a Series C in Nov 2024.
$150M
Amount raised
Not disclosed
Post-money valuation
12
Investors
1 lead
Valuation
What this round says about the price
Enveda did not disclose a valuation in this round. It came 10 months after Enveda's Series C. It is 21% of the $715M Enveda has raised in the venture rounds on record. Enveda raised again 12 months later: a Series E round of $311M in Sep 2026, at $2.00B post-money.
Enveda's funding rounds
Enveda has 6 venture rounds on record. This one is highlighted.
- Seed 27 Dec 2020, led by True Ventures $4.9M
- Series A 22 Jun 2021, led by Lux Capital $51M
- Series B 21 Dec 2022, led by Dimension $68M
- Series C 21 Nov 2024, led by Kinnevik and FPV Ventures $130M
- Series D this round 4 Sep 2025, led by Premji Invest $150M
- Series E 23 Sep 2026, led by Catalio Capital Management $311M$2.00B post-money
Investors
Who put money in
Premji Invest led the round with 11 other firms. Premji Invest and Baillie Gifford had backed Enveda before.
Lead investor
- Premji Invest backs 50 venture-backed companies existing investor
Also in the round
- Baillie Gifford existing investor
- Kinnevik backs 55 venture-backed companies new investor
- Lingotto Investment Management new investor
- backs 2 venture-backed companies new investor
- backs 39 venture-backed companies new investor
- backs 13 venture-backed companies new investor
- backs 24 venture-backed companies new investor
- backs 3 venture-backed companies new investor
- KKR backs 104 venture-backed companies new investor
- backs 33 venture-backed companies new investor
- Lux Capital backs 194 venture-backed companies new investor
Joined the board: Mikael Dolsten (Pfizer).
Use of proceeds
What the money is for
According to the announcement, the money goes to product development, scaling operations and working capital.
- Product development
- Scaling operations
- Working capital
Comparable rounds
How it compares
13 Series D rounds in Biotechnology within a year either side disclosed an amount; the median was $97M, and this round was 1.6 times the median. The closest in time, other companies' Series D rounds in Biotechnology:
| Company | Announced | Amount | Post-money | Led by |
|---|---|---|---|---|
| Kriya Therapeutics Biotechnology | 10 Sep 2025 | $320M | not disclosed | Patient Square Capital and Premji Invest |
| Biotechnology | 30 Sep 2025 | $125M | not disclosed | Sanofi Ventures and Viking Global |
| Biotechnology | 24 Jun 2025 | $97M | not disclosed | healthcare investor |
| Biotechnology | 4 Jun 2025 | $50M | not disclosed | not named |
| Pathos Biotechnology | 15 May 2025 | $365M | $1.60B | not named |
| Biotechnology | 12 Mar 2025 | $35M | not disclosed | RA Capital |
| Biotechnology | 3 Mar 2025 | $700K | not disclosed | not named |
| Biotechnology | 8 Apr 2026 | $80M | not disclosed | not named |
Sources
Where this comes from
Reported by 4 sources.
Questions
Frequently asked
How much did Enveda raise in its Series D round?
Enveda raised $150M in its Series D round, announced in Sep 2025.
Who led Enveda's Series D round?
Premji Invest led it, with Baillie Gifford, Kinnevik, Lingotto Investment Management, Peakline Partners and FPV Ventures and 6 more.
What was Enveda's valuation at the Series D round?
It was not disclosed.
How does it compare with other Series D rounds in Biotechnology?
13 Series D rounds in Biotechnology within a year either side disclosed an amount; the median was $97M, and this round was 1.6 times the median.
Did Enveda raise again after this round?
Yes: a Series E round in Sep 2026 of $311M at $2.00B post-money.